Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8908 results

  1. Asthma: objective tests (IND187)

    This guidance has been updated and replaced by NICE indicator 272.

    Withdrawn indicator

  2. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  3. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  4. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  5. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Withdrawn advice

  6. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  7. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  8. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This advice has been updated and replaced by NICE healthtech guidance 708.

    Withdrawn advice

  9. Magtrace and Sentimag for locating sentinel lymph nodes (MIB263)

    This advice has been updated and replaced by NICE healthtech guidance 642.

    Withdrawn advice

  10. Alcohol: school-based interventions (PH7)

    This guideline has been updated and replaced by NICE guideline NG135.

    Withdrawn guideline

  11. Physical activity and the environment (PH8)

    This guideline has been updated and replaced by NICE guideline NG90.

    Withdrawn guideline

  12. Community engagement (PH9)

    This guidance has been updated and replaced by NICE guideline NG44.

    Withdrawn guideline

  13. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

    Withdrawn guideline

  14. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  15. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued